Cel-Sci Corporation Running On Acquisition Rumors

Shares of Cel-Sci Corporation

are running sharply higher today, on rumors that the biotech company may be bought out by a larger pharmaceutical company. As of now, there is no definitive rumor on which company may acquired CVM. CVM has a roughly $130 million market cap, so it is cheap based on a market cap metric. CEL-SCI Corporation is best known for its Multikine drug, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. Shares of CVM are up 7 cents or nearly $13 today to 62 cents.